Biotech news on July 14, 2026

1. 0109:45 UTC

   PBS review of MS treatments Ocrevus and Kesimpta reported

   11 outlets · first: maitlandmercury.com.au Pharma

   Reported by maitlandmercury.com.au, oberonreview.com.au, moreechampion.com.au, nvi.com.au, gloucesteradvocate.com.au, ulladullatimes.com.au, and 5 more outlets.

   • Kesimpta (ofatumumab)
   • Ocrevus (ocrelizumab)

   Full coverage: every report, when each was published, and who was named (11 outlets)

2. 0216:20 UTC

   Cayman court orders Apple Tree partner to forfeit fund oversight

   2 outlets · first: BioPharma Dive Funding

   Machine summary A Cayman Islands court ordered a family trust to forfeit oversight of the Apple Tree Partners venture fund, according to BioPharma Dive. The ruling adds to an ongoing legal dispute that has already resulted in a bankruptcy filing by Apple Tree Partners.

   Reported by BioPharma Dive.

   • Apple Tree Partners
   • Rigmora

   Full coverage: every report, when each was published, and who was named (2 outlets)

3. 0318:00 UTC

   Reports: most new Ebola cases in eastern Congo from unknown chains

   2 outlets · first: mcall.com Clinical trial

   Machine summary Most new Ebola cases in eastern Congo are from unknown chains of transmission, according to reports. The outbreak is outpacing the response, the reports said.

   1. The outbreak is outpacing the response, according to reports.

   Reported by mcall.com and Ksat.

   • Congo (Democratic Republic)

4. 0415:00 UTC

   DelveInsight forecast projects 47% CAGR for Alport syndrome market through 2036

   2 outlets · first: Pr Newswire Pharma Mostly press releases

   Machine summary A new DelveInsight forecast projects a 47% CAGR for the Alport syndrome market through 2036, fueled by a pipeline of gene and targeted therapies. The report states that ELX-02 from Eloxx has an 8-week dosing interval, while Bayer and Novartis are advancing competing therapies.

   1. DelveInsight projects the Alport syndrome market to grow at a 47% compound annual growth rate (CAGR) from 2022 through 2036.
   2. The forecast covers seven major markets: United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan.
   3. Key pipeline therapies include ELX-02 (Exaluren) from Eloxx Pharmaceuticals, Vonafexor from Enyo Pharma, BAY3401016 from Evotec/Bayer, Setanaxib from Asahi Kasei, and Atrasentan from Novartis/Chinook Therapeutics.
   4. The DelveInsight report integrates epidemiology, treatment practices, and competitive analysis, providing forecasts through 2034.

   Reported by Pr Newswire and finanznachrichten.de.

   • Novartis
   • Bayer
   • Evotec
   • Setanaxib
   • ELX-02 (Exaluren)
   • Eloxx Pharmaceuticals

5. 0518:45 UTC

   ACROBiosystems receives PMDA material suitability confirmation for GMP-grade IL-15

   2 outlets · first: thailand-business-news.com Gene therapy

   Machine summary ACROBiosystems said it received the "Material Suitability Confirmation for Regenerative Medicine Products" from Japan's Pharmaceuticals and Medical Devices Agency for its GMP-grade Human IL-15 protein. The company said the confirmation validates its quality system and compliance capabilities in core raw materials for cell and gene therapy.

   1. ACROBiosystems said it officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号) from the PMDA for its GMP-grade Human IL-15 protein.
   2. According to the company, this confirmation belongs to a formal PMDA assessment framework covering essential raw materials for regenerative medical products, including CAR-T, CAR-NK, and TCR-T immunotherapies.
   3. ACROBiosystems said the confirmation declares that the material's composition and preparation do not employ any human or animal-derived components that would need documentation showing adherence to biological raw material guidelines.
   4. The company said its main active component is recombinant human IL-15 protein at 0.3 g/L, and it said this completely satisfies the PMDA's safety-related evaluation requirements.
   5. ACROBiosystems said it credited the confirmation to its GMP production system, a design that contains no animal-derived components, and full functional validation.

   Reported by thailand-business-news.com and balticbusinessnews.com.

   • PMDA
   • IL-15
   • ACROBiosystems

6. 0619:45 UTC

   CDC issues health alert on cyclosporiasis outbreak with 5,100 suspected cases

   1 outlet · first: iHeartRadio Pharma

   Machine summary The CDC issued a health alert on a cyclosporiasis outbreak with 5,100 suspected cases.

   1. Michigan confirms over 1,200 cases, more than 24 times its annual average of 50; at least 86 hospitalizations nationally, most in Michigan and Ohio.
   2. CDC reports 1,645 laboratory-confirmed cases and an additional 5,100 under investigation.
   3. No specific food source identified; traceback investigation ongoing, with previous outbreaks linked to fresh produce like raspberries and leafy greens.

   Reported by iHeartRadio.

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.